Please assess the completion status of the following clinical trial:

Trial Title: Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Previously untreated adults with chronic hepatitis C (hepatitis C virus ribonucleic acid \[HCV RNA\] quantitative polymerase chain reaction \[qPCR\] plasma positive)~* Individuals with HCV genotype 1 (mixed 1a/1b is acceptable)~* Compensated liver disease~* Pretreatment liver biopsy slides available~* Adults aged 18-70~* Individuals weighing 88-275 pounds (40-125 kg)~* Free from substance abuse for past 2 years~* Those suffering from diabetes and/or hypertension must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)~* Patients and partners of patients willing to use adequate contraception during the course of the study~* Hematology laboratory results of:~  * Hemoglobin (HGB) ≥ 12 g/dL for females or ≥ 13g/dL for males~ * White Blood Cell Count (WBC) ≥ 3,000/mm\^3~ * Neutrophils ≥ 1,500/mm\^3~ * Platelets ≥ 80,000/mm\^3~* Chemistry laboratory results of:~  * Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and direct bilirubin~ * Antinuclear antibody (ANA) ≤ 1:320~ * Fasting Glucose 70-140 mg/dL Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, glycosylated hemoglobin \[HbA1C\] must be ≤ 8.5%~EXCLUSION CRITERIA:~* Previous hepatitis C treatment~* Pregnant women or partners of pregnant women~* Patients or partners of patients who intend to become pregnant any time during the 48 weeks~* Women who are breastfeeding~* Individuals with liver disease not caused by hepatitis C~* Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV)~* Patients with a history of liver cancer (hepatocellular carcinoma)~* Known blood disorders such as hemoglobinopathy, coagulopathy, or glucose-6-phosphate dehydrogenase \[G6PD\] deficiency~* Body organ transplant~* Any known or suspected cancer within the past 5 years~* Individuals who currently use epoetin \[EPO\], granulocyte colony stimulating factor \[G-CSF\] and/or granulocyte monocyte colony stimulating factor \[GM-CSF\]~* Those having a history of or active clinical gout~* Individuals who have chronic pulmonary disease~* Individuals who have a medical condition that would likely require systemic steroids~* Those with a history of central nervous system (CNS trauma) or seizure disorders~* Current or previous use of lithium or antipsychotic drugs~* Individuals who currently have or show signs of moderate to severe depression or history of significant psychiatric disorders~* Patients with clinically significant electrocardiogram (ECG) abnormalities~* Individuals with serious heart problems such as those who have had a heart attack, uncontrolled high blood pressure, or other heart problems~* Patients that weigh \> 231-275 pounds (105-125 kg) AND have a body mass index (BMI) \> 30 AND have 3 or more of the risk factors below: (a) Strong family history of coronary heart disease (CHD) which includes 2 or more first-degree relatives with CHD or family history of early CHD at age \< 55 for male relatives or \< 65 for female relatives (b) Individuals with abnormal total cholesterol and/or sub fractions (uncontrolled hypercholesterolemia) (c) Diabetes (d) Hypertension (e) Smoking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PegIntron 1.5 ug/kg/wk plus REBETOL (Type: EXPERIMENTAL): PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
- PegIntron 1.0 ug/kg/wk plus REBETOL (Type: EXPERIMENTAL): PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
- PEGASYS 180 ug/wk Plus COPEGUS (Type: ACTIVE_COMPARATOR): PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).